Celgene (CELG) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura
October 24, 2014 9:48 AM EDTNomura Securities analyst Ian Somaiya reiterated a Buy and Top Pick rating while boosting his price target on Celgene (NASDAQ: CELG) to $136.00 (from $124.00) following results.
Somaiya commented, "We are increasing our Revlimid estimates and TP to $136, from $124, as we see continued strength in Revlimid sales heading... More
Celgene (CELG) Price Target Raised to $134 at Deutsche Bank
October 24, 2014 9:07 AM EDTDeutsche Bank maintained a Buy rating on Celgene (NASDAQ: CELG) and raised its price target to $134.00 (from $115.00). Analyst Robyn Karnauskas said Celgene was emerging as top pick for 2015.
"The focus of the 3Q call was the strong Otezla launch, and the pipeline,... More



